FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patents. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds.

Subscribe to updates on this page: Antagonist RSS RSS

Date/App# patent app List of recent Antagonist-related patents
04/10/14
20140101785
 Genetically encoded calcium indicators and methods of use patent thumbnailnew patent Genetically encoded calcium indicators and methods of use
Genetically encoded calcium indicator (geci) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of g-protein coupled receptor (gpcr) or ion channels and methods of monitoring neural activity also are provided..
04/10/14
20140100255
 Novel compounds as antagonists or inverse agonists at opioid receptors patent thumbnailnew patent Novel compounds as antagonists or inverse agonists at opioid receptors
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.. .
04/10/14
20140100242
 Inhibition of quorum sensing-mediated processes in bacteria patent thumbnailnew patent Inhibition of quorum sensing-mediated processes in bacteria
Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified.
04/10/14
20140100237
 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation patent thumbnailnew patent Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
Compounds are provided that act as potent antagonists of the ccr2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr2-mediated diseases and as controls in assays for the identification of ccr2 antagonists..
04/10/14
20140100230
 Methods and compositions for treating anxiety patent thumbnailnew patent Methods and compositions for treating anxiety
Methods of treating a trpc5 mediated disorder in a subject by administering an effective amount of a trpc5 antagonist, such as a compound disclosed herein, are described.. .
04/10/14
20140100208
 Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding patent thumbnailnew patent Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
Progesterone antagonists and sprm are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days..
04/10/14
20140100194
 Cold menthol receptor-1 antagonists patent thumbnailnew patent Cold menthol receptor-1 antagonists
The invention is directed to trpm8 antagonists of formula (i). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating trpm8-mediated disorders.
04/10/14
20140100163
 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide patent thumbnailnew patent Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (am) or gastrin releasing peptide (grp) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients..
04/10/14
20140099708
 Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders patent thumbnailnew patent Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of both the heterodimeric il12 and il23 receptors. The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifnγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifnγ production, il12 and/il23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
04/10/14
20140099387
 Compositions and methods for treatment patent thumbnailnew patent Compositions and methods for treatment
The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
04/10/14
20140099369
new patent Tamper-resistant oral opioid agonist formulations
Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.. .
04/10/14
20140099366
new patent Composition containing two anti-dementia drugs
An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well.
04/10/14
20140099325
new patent Human monoclonal antibodies to ctla-4
In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic t-lymphocyte antigen 4 (ctla-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (cdrs), specifically from within fr1 and/or cdr1 through cdr3 and/or within fr4, are provided.
04/10/14
20140099323
new patent Methods for treatment of inflammatory diseases
It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
04/10/14
20140099310
new patent Cancer targets and uses thereof
Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“cat”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using cat.
04/03/14
20140094513
Composition and method for neuroprotection against excitotoxic injury
The present invention discloses the combined treatment of memantine (n-methyl-d-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea polyphenols in preventing or treating clinical excitotoxic injury such as brain trauma, brain ischemia, epilepsy, and alzheimer's disease..
04/03/14
20140094512
Method of modulating the degree of adipose tissue deposited intramuscularly
The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in cattle by administration of a retinoic receptor antagonist or inverse agonist and compounds for use in such method.. .
04/03/14
20140094482
Benzazocine-ring compound inhibition of tau hyperphosphorylation
A method of inhibiting hyperphosphorylation of the tau protein and/or a tlr4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a flna-binding effective amount of a flna-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin a (flna) of seq id no: 1.
04/03/14
20140094444
Compositions and methods for tissue engineering and cell based therapies
The present application discloses strategies to recruit and mobilize stem cells using s1p receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, s1p1/s1p3 activation with fty720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (epcs) with the potential to increase microvascular remodeling.
04/03/14
20140094442
Combinations comprising anti-muscarinic agents and corticosteroids
Combinations comprising (a) a corticosteroid and (b) an antagonist of m3 muscarinic receptors which is 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion x, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.. .
04/03/14
20140094413
Hepatocyte growth factor (hgf) mimics as therapeutic agents
Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, alzheimer's disease, parkinson's disease, amyotrphic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury, diabetes and metabolic syndrome, cancer, and defective wound healing..
04/03/14
20140094412
Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications
The present invention is related to new peptide antagonists of αvβ3 receptor, designed on the basis of the crystal structure of integrin αvβ3 in complex with c(rgdf[nme]v) and the nmr structure of echistatin. These peptides are potent and selective antagonists of the αvβ3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for αvβ3-targeted therapy and imaging..
04/03/14
20140094409
Antagonist for (pro)renin receptor for the treatment of hypertension and diabetes
Brain prorenin and the (pro)renin receptor (prr) have a functional role in the development of hypertension. The present disclosure presents functional prr antagonistic peptides (e.g., pr10, pr20, pr30, and pr40).
04/03/14
20140093508
Toll-like 3 receptor antagonists
Toll like receptor 3 (tlr3) antibody antagonists, polynucleotides encoding tlr3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.. .
04/03/14
20140093492
Method for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
M-csf antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal.. .
04/03/14
20140093476
Methods for treating pain
Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques.
03/27/14
20140088178
Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
Or a pharmaceutically acceptable salt thereof, each in an amount that when in combination with the other is effective to treat the mammalian subject.. .
03/27/14
20140088105
Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (crf1) receptor antagonists.. .
03/27/14
20140088086
Compounds and methods for treatment of hypertension
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2b antagonists.
03/27/14
20140088004
Hepatocyte growth factor mimics as therapeutic agents
Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing..
03/27/14
20140087993
Pepducin design and use
Disclosed here is the rational design and use of potent and specific gpcr antagonist pepducins based on gpcr regions such as the third intracellular loop and adjacent regions.. .
03/27/14
20140087357
Organ transplant solutions and methods for transplanting organs
A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the c5a anaphylatoxin which is a c5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated..
03/27/14
20140087050
Chia seed composition
A composition of matter is disclosed and formed from a stable, defatted whole grain flour derived from salvia hispanica l. Whole ground seed using a suitable solvent that is free of cyanogenic glycosides, vitamin antagonists, and gluten.
03/27/14
20140086938
Methods of inhibiting tumor growth using ttk antagonists
The present invention relates to methods for treating ttk positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a ttk antagonist. The invention also provides compositions comprising a ttk antagonist and a her-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of ttk in a tumor sample from a subject..
03/27/14
20140086934
Method for treating intraocular neovascular diseases
A method is provided for administering to a mammal suffering from, or at risk for, an intraocular neovascular disorder with regular dosing of a therapeutically effective amount of vegf antagonist, followed by less frequent dosing of a therapeutically effective amount of vegf antagonist.. .
03/27/14
20140086920
Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8 associated disorders
The disclosure provides novel molecules related to growth and differentiation factor-8 (gdf-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit gdf-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (als).
03/20/14
20140081025
Heteroaromatic ring derivative
Or a pharmaceutically acceptable salt thereof is based on orexin (ox) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.. .
03/20/14
20140080863
Muscarinic acetylcholine receptor antagonists
Muscarinic acetylcholine receptor antagonists and methods of using them are provided.. .
03/20/14
20140080855
8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
Wherein r2, r7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..
03/20/14
20140080854
Peripheral opioid receptor antagonists and uses thereof
Wherein x−, r1, and r2 are as defined herein, and compositions thereof.. .
03/20/14
20140080811
Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++ activated atp-sensitive cation channels regulatd by sur1 channels
Nsc antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, alzheimer's disease (ad).
03/20/14
20140080794
Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression.
03/20/14
20140080771
Method for treating rhinitis and sinusitis by rhamnolipids
The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid.
03/20/14
20140080756
2,3-dihydro-1h-inden-1-yl-2,7-diazaspiro[3.5]nonane derivatives
A pharmaceutically salt thereof wherein r1, r2, ra, l, z, z1 and z2 are as defined herein, that act as ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the ghrelin receptor.. .
03/20/14
20140079784
Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
This invention provides specifically formulated lfa-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the lfa-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate.
03/20/14
20140079769
Methods for predicting the progression and treating a chronic kidney disease in a patient
The present invention relates to a method for predicting the progression of chronic kidney disease (ckd) in a patient and also to an inhibitor of ngal gene expression or an ngal antagonist for use in the prevention or the treatment of ckd.. .
03/20/14
20140079719
Il-17 antagonistic antibodies
An il-17 binding molecule, in particular an antibody to human il-17, more preferably a human antibody to human il-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an il-17 mediated disease or disorder, e.g. Rheumatoid arthritis..
03/20/14
20140079702
Antagonists of il-6 to raise albumin and/or lower crp
The present invention is directed to therapeutic methods using il-6 antagonists such as antibodies and fragments thereof having binding specificity for il-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum c-reactive protein level or a reduced serum albumin level prior to treatment.
03/20/14
20140079700
Method for promoting bone growth using activin-actriia antagonists
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.. .
03/20/14
20140079695
Preventive agent for vasculitis
To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (il-6) antagonist as an active ingredient.. .
03/20/14
20140079669
Formulation and method for treating plants to control or suppress a plant pathogen
The present invention provides formulations and methods for preventing, suppressing, treating, or controlling pre- or post-harvest disease or decay in plants. In the inventive method, plants are contacted with a formulation including an antagonistic microorganism and a booster composition.
03/20/14
20140079640
Novel treatment of pain
The present invention relates to the use of an antagonist of the non-selective cation channel trpm3 as a medicine for the treatment of pain. The present invention further relates to a method for identification of novel compounds for the treatment of pain, such as trpm3-antagonists and compounds that modulate the activity or expression of trpm3.
03/13/14
20140073666
Compositions and methods for treatment
The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
03/13/14
20140073664
Combination dopamine antagonist and opiate receptor antagonist treatment of addictive behavior
The present invention is directed to a method of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a dopamine antagonist and a opiate receptor antagonist or a composition comprising same. Further provided are pharmaceutical compositions comprising, as active substances, at least one dopamine antagonist and at least one opiate receptor antagonist..
03/13/14
20140073651
Benzamide derivatives as p2x7 receptor antagonists
Wherein r1, r2, r3, r4, r5, r6, n and y are as defined in the description, their preparation and their use as pharmaceutically active compounds.. .
03/13/14
20140073649
Isotopically enriched arylsulfonamide ccr3 antagonists
Provided herein are isotopically enriched arylsulfonamides, for example, of formula i, that are useful for modulating ccr3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a ccr3-mediated disease, disorder, or condition..
03/13/14
20140073627
Bradykinin b1 antagonists
Wherein r1, r1a, r1b, r2, r3 and x, x1, x2, x3 have the meaning as cited in the description and the claims. Said compounds are useful as bradykinin b1 antagonists.
03/13/14
20140073590
Methods for treating pulmonary hypertension
The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting adp-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible p2y12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments..
03/13/14
20140073585
Peptide inhibitors of hausp deubiquitinase
Two virf4 (kaposi's-sarcoma-associated-herpesvirus virf4) peptides, vif1, corresponding to aa202-216 of virf4, and vif2, corresponding to aa220-236 of virf4, are potent and selective hausp antagonists. The vif1 and vif2 peptides robustly suppress hausp dub enzymatic activity, ultimately leading to p53-mediated anti-cancer activity.
03/13/14
20140073574
Therapy for complications of diabetes
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
03/13/14
20140073562
Nasal delivery
A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.. .
03/13/14
20140073557
Fgfri-based antagonists with improved glycosaminoglycan affinity and methods of using same
A novel approach for inhibiting fgf2/fgfr1-mediated signalling is presented which is based on fgfr1 mutations to introduce higher affinity for the natural gag co-receptors into the soluble part of the fgf1 receptor, preferably into the d2/d3 domains. Such recombinant drugs are expected to disrupt the natural fgf2/fgfr1/gag triple complex by competing with the wtfgfr1 for gag binding.
03/13/14
20140073556
Antagonists of the interleukin-1 receptor
The present invention discloses novel peptides derived from the il-1 receptor antagonist protein (il1 ra), capable of binding to the cell surface il-1 receptor 1 (il1 r1) and interfere with the binding of il-1 to il1 r1. This binding thus effectively antagonises the inflammatory effects of il-1, such as by reducing tnf-alpha secretion from macrophages.
03/13/14
20140072933
Artificial teeth
The invention enables artificial molar teeth to be arranged at appropriate positions according to the oral cavity environment of each patient without requiring advanced techniques or experience. The artificial molar teeth have maxillary molar teeth and mandibular molar teeth arranged so as to form a pair on denture bases to be mounted on upper and lower jaws in an oral cavity, in which one cusp out of the cusps of the maxillary molar teeth and the mandibular molar teeth is engaged with a fossa of the antagonist, and at least one of the other cusps is engaged with a groove of the antagonist..
03/13/14
20140072646
Thyroid hormone analogs and methods of use
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed..
03/13/14
20140072635
Thyroid hormone analogs and methods of use
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed..
03/13/14
20140072583
Methods for treating atopic dermatitis by administering an il-4r antagonist
The present invention provides methods for treating atopic dermatitis (ad). Also provided are methods for improving one or more ad-associated parameter(s), and methods for decreasing the level of at least one ad-associated biomarker in a subject in need thereof.
03/13/14
20140072576
Chemokine receptor antagonists and use thereof
Wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against cxcr4 and is therefore useful as a preventive and/or therapeutic agent for cxcr4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy..
03/06/14
20140066475
Method for treating pruritus
Benzomorphan compounds are found to be useful for treating, ameliorating or preventing pruritus, and in particular pruritus associated with (including induced by) the administration of opioids. Antipruritic activity is believed to be mediated through the dual action of the compounds as mu opioid receptor antagonists and kappa opioid receptor agonists.
03/06/14
20140066467
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.. .
03/06/14
20140066446
2,5-disubstituted arylsulfonamide ccr3 antagonists
Provided herein are 2,5-disubstituted arylsulfonamide ccr3 antagonists, e.g., compounds of formula i, and pharmaceutical compositions thereof: also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a ccr3-mediated disorder, disease, or condition.. .
03/06/14
20140066438
Dopamine receptor d2 antagonist for prevention and treatment of flavivirus infection
Methods for preventing and/or treating flavivirus infection are disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a dopamine d2 receptor antagonist in an amount effective for preventing and/or treating flavivirus infection; and b) a pharmaceutically acceptable carrier.
03/06/14
20140066425
Androgen receptor antagonists and uses thereof
Disclosed are substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds. The compounds and compositions can be used for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss and hypertrichosis..


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3384

3409

0 - 1 - 74